renal

Hospitals can license this animation for patient education and content marketing initiatives. Learn more: …

Initiating treatment with a sodium–glucose cotransporter-2 (SGLT2) inhibitor rather than a glucagon-like peptide-1 receptor agonist (GLP-1RA) is associated with better renal outcomes in people with type 2 diabetes, according to …

The Cureus Journal of Medical ScienceAngiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-AnalysisType 2 diabetes mellitus (T2DM) …

CureusComparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSodium-glucose cotransporter-2 (SGLT2) inhibitors …

In a groundbreaking study, researchers have identified isthmin-1 as a potential biomarker linked to the progression of renal function decline in patients suffering from type 2 diabetes mellitus. The findings, …

CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing …

Si deseas ver más imágenes médicas en 3D con precisión científica, suscríbase a nuestro canal: …

When treating patients with T2DM, one of the main challenges physicians face is understanding the complexity of individual patient profiles. This complexity arises not only from the multidimensional nature of …